[1] Maron B. Clinical Course and Management of Hypertrophic Cardiomyopathy. The New England journal of medicine 2018;379:655-668.
[2] Hensley N, Dietrich J, Nyhan D, Mitter N, Yee M, Brady M. Hypertrophic cardiomyopathy: a review. Anesthesia and Analgesia 2015;120:554-569.
[3] Firth J. Cardiology: hypertrophic cardiomyopathy. Clinical medicine (London, England) 2019;19:61-63.
[4] Bulun S. Uterine fibroids. The New England journal of medicine 2013;369:1344-1355.
[5] Sabater-Molina M, Pérez-Sánchez I, Hernández Del Rincón J, Gimeno J. Genetics of hypertrophic cardiomyopathy: A review of current state. Clinical Genetics 2018;93:3-14.
[6] Teekakirikul P, Zhu W, Huang H, Fung E. Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules 2019;9:
[7] Bonaventura J, Veselka J. Genetic testing in patients with hypertrophic cardiomyopathy. Vnitrni Lekarstvi 2019;65:652-658.
[8] Drezner J, Malhotra A, Prutkin J, Papadakis M, Harmon K, Asif I, et al. Return to play with hypertrophic cardiomyopathy: are we moving too fast? A critical review. British Journal of Sports Medicine 2021;
[9] Maron B, Maron M. Hypertrophic cardiomyopathy. Lancet (London, England) 2013;381:242-255.
[10] Kapplinger J, Landstrom A, Bos J, Salisbury B, Callis T, Ackerman M. Distinguishing hypertrophic cardiomyopathy-associated mutations from background genetic noise. Journal of Cardiovascular Translational Research 2014;7:347-361.
[11] Mantione K, Kream R, Kuzelova H, Ptacek R, Raboch J, Samuel J, et al. Comparing bioinformatic gene expression profiling methods: microarray and RNA-Seq. Medical science monitor basic research 2014;20:138-142.
[12] Hung J, Weng Z. Analysis of Microarray and RNA-seq Expression Profiling Data. Cold Spring Harbor protocols 2017;2017:
[13] Chen D, Kong X, Shen X, Huang M, Zheng J, Sun J, et al. Identification of Differentially Expressed Genes and Signaling Pathways in Acute Myocardial Infarction Based on Integrated Bioinformatics Analysis. Cardiovascular Therapeutics 2019;2019:8490707.
[14] Vernon S, Hansen T, Kott K, Yang J, O'Sullivan J, Figtree G. Utilizing state-of-the-art "omics" technology and bioinformatics to identify new biological mechanisms and biomarkers for coronary artery disease. Microcirculation (New York, N.Y. : 1994) 2019;26:e12488.
[15] Andreasen C, Nielsen J, Refsgaard L, Holst A, Christensen A, Andreasen L, et al. New population-based exome data are questioning the pathogenicity of previously cardiomyopathy-associated genetic variants. European journal of human genetics : EJHG 2013;21:918-928.
[16] Lopes L, Rahman M, Elliott P. A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart (British Cardiac Society) 2013;99:1800-1811.
[17] Walsh R, Buchan R, Wilk A, John S, Felkin L, Thomson K, et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. European Heart Journal 2017;38:3461-3468.
[18] Angarica V, Del Sol A. Bioinformatics Tools for Genome-Wide Epigenetic Research. Advances in Experimental Medicine and Biology 2017;978:489-512.
[19] Li N, Wu H, Geng R, Tang Q. Identification of Core Gene Biomarkers in Patients with Diabetic Cardiomyopathy. Disease Markers 2018;2018:6025061.
[20] Davis S, Meltzer P. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics (Oxford, England) 2007;23:1846-1847.
[21] Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England journal of medicine 2018;379:2108-2121.
[22] Fabregat A, Sidiropoulos K, Viteri G, Forner O, Marin-Garcia P, Arnau V, et al. Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinformatics 2017;18:142.
[23] Gaudet P, Škunca N, Hu J, Dessimoz C. Primer on the Gene Ontology. Methods in molecular biology (Clifton, N.J.) 2017;1446:25-37.
[24] Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research 1999;27:29-34.
[25] Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Research 2000;28:27-30.
[26] Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Research 2015;43:D447-452.
[27] Szklarczyk D, Gable A, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research 2019;47:D607-D613.
[28] Dang H, Ye Y, Zhao X, Zeng Y. Identification of candidate genes in ischemic cardiomyopathy by gene expression omnibus database. BMC Cardiovascular Disorders 2020;20:320.
[29] Wang D, Liu B, Xiong T, Yu W, She Q. Investigation of the underlying genes and mechanism of familial hypercholesterolemia through bioinformatics analysis. BMC Cardiovascular Disorders 2020;20:419.
[30] Varma P, Neema P. Hypertrophic cardiomyopathy: part 1 - introduction, pathology and pathophysiology. Annals of Cardiac Anaesthesia 2014;17:118-124.
[31] Coats C, Elliott P. Genetic biomarkers in hypertrophic cardiomyopathy. Biomarkers in Medicine 2013;7:505-516.
[32] Geier C, Perrot A, Ozcelik C, Binner P, Counsell D, Hoffmann K, et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 2003;107:1390-1395.
[33] MacIver D, Clark A. Contractile Dysfunction in Sarcomeric Hypertrophic Cardiomyopathy. Journal of Cardiac Failure 2016;22:731-737.
[34] Kraft T, Montag J, Radocaj A, Brenner B. Hypertrophic Cardiomyopathy: Cell-to-Cell Imbalance in Gene Expression and Contraction Force as Trigger for Disease Phenotype Development. Circulation Research 2016;119:992-995.
[35] Prondzynski M, Mearini G, Carrier L. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy. Pflugers Archiv : European journal of physiology 2019;471:807-815.
[36] Zhou X, Liao W, Liao J, Liao P, Lu H. Ribosomal proteins: functions beyond the ribosome. Journal of Molecular Cell Biology 2015;7:92-104.
[37] Schroeder A, Allahyari M, Vogler G, Missinato M, Nielsen T, Yu M, et al. Model system identification of novel congenital heart disease gene candidates: focus on RPL13. Human Molecular Genetics 2019;28:3954-3969.
[38] Cripps R, Olson E. Control of cardiac development by an evolutionarily conserved transcriptional network. Developmental Biology 2002;246:14-28.
[39] Martinez E, Passariello C, Li J, Matheson C, Dodge-Kafka K, Reigan P, et al. RSK3: A regulator of pathological cardiac remodeling. IUBMB life 2015;67:331-337.
[40] Doroudgar S, Hofmann C, Boileau E, Malone B, Riechert E, Gorska AA, et al. Monitoring Cell-Type-Specific Gene Expression Using Ribosome Profiling In Vivo During Cardiac Hemodynamic Stress. Circulation Research 2019;125:431-448.
[41] Meng Z, Moroishi T, Guan K. Mechanisms of Hippo pathway regulation. Genes and Development 2016;30:1-17.
[42] Wang J, Liu S, Heallen T, Martin J. The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration. Nature reviews. Cardiology 2018;15:672-684.
[43] Zhou Q, Li L, Zhao B, Guan K. The hippo pathway in heart development, regeneration, and diseases. Circulation Research 2015;116:1431-1447.
[44] Johansen A, Molkentin J. Hippo signaling does it again: arbitrating cardiac fibroblast identity and activation. Genes and Development 2019;33:1457-1459.
[45] Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson R, et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science (New York, N.Y.) 2011;332:458-461.
[46] Leach J, Heallen T, Zhang M, Rahmani M, Morikawa Y, Hill M, et al. Hippo pathway deficiency reverses systolic heart failure after infarction. Nature 2017;550:260-264.
[47] Wang P, Mao B, Luo W, Wei B, Jiang W, Liu D, et al. The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy. Basic Research in Cardiology 2014;109:435.
[48] Vega R, Konhilas J, Kelly D, Leinwand L. Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. Cell Metabolism 2017;25:1012-1026.
[49] Mohan M, Jha B, Gupta M, Vasudevan N, Martelli E, Mosinski J, et al. Phosphoinositide 3-kinase γ inhibits cardiac GSK-3 independently of Akt. Science signaling 2013;6:ra4.
[50] Taniyama Y, Ito M, Sato K, Kuester C, Veit K, Tremp G, et al. Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. Journal of Molecular and Cellular Cardiology 2005;38:375-385.
[51] Hou N, Mai Y, Qiu X, Yuan W, Li Y, Luo C, et al. Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice. Frontiers in Pharmacology 2019;10:998.
[52] Wang X, Pan J, Liu D, Zhang M, Li X, Tian J, et al. Nicorandil alleviates apoptosis in diabetic cardiomyopathy through PI3K/Akt pathway. Journal of Cellular and Molecular Medicine 2019;23:5349-5359.
[53] Ma L, Li X, Ji H, Liu Y, Li E. Baicalein Protects Rats with Diabetic Cardiomyopathy Against Oxidative Stress and Inflammation Injury via Phosphatidylinositol 3-Kinase (PI3K)/AKT Pathway. Medical science monitor : international medical journal of experimental and clinical research 2018;24:5368-5375.
[54] Dong W, Guan F, Zhang X, Gao S, Liu N, Chen W, et al. Dhcr24 activates the PI3K/Akt/HKII pathway and protects against dilated cardiomyopathy in mice. Animal models and experimental medicine 2018;1:40-52.
[55] Bairwa S, Parajuli N, Dyck J. The role of AMPK in cardiomyocyte health and survival. Biochimica et Biophysica Acta 2016;1862:2199-2210.
[56] Banerjee S, McGaffin K, Huang X, Ahmad F. Activation of cardiac hypertrophic signaling pathways in a transgenic mouse with the human PRKAG2 Thr400Asn mutation. Biochimica et Biophysica Acta 2010;1802:284-291.
[57] Magida J, Leinwand L. Metabolic crosstalk between the heart and liver impacts familial hypertrophic cardiomyopathy. EMBO Molecular Medicine 2014;6:482-495.
[58] Chen H, Untiveros G, McKee L, Perez J, Li J, Antin P, et al. Micro-RNA-195 and -451 regulate the LKB1/AMPK signaling axis by targeting MO25. PloS One 2012;7:e41574.
[59] Zhou Y, He X, Chen Y, Huang Y, Wu L, He J. Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation. Biochemical and Biophysical Research Communications 2015;468:394-399.
[60] Marian A, Salek L, Lutucuta S. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Medica 2001;92:435-451.
[61] Li T, Jiang S, Yang Z, Ma Z, Yi W, Wang D, et al. Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy? Cellular and molecular life sciences : CMLS 2017;74:1413-1429.
[62] do Vale G, Ceron C, Gonzaga N, Simplicio J, Padovan J. Three Generations of β-blockers: History, Class Differences and Clinical Applicability. Current Hypertension Reviews 2019;15:22-31.
[63] Xiang Y. Compartmentalization of beta-adrenergic signals in cardiomyocytes. Circulation Research 2011;109:231-244.
[64] Cruz-Topete D, Myers P, Foley J, Willis M, Cidlowski J. Corticosteroids Are Essential for Maintaining Cardiovascular Function in Male Mice. Endocrinology 2016;157:2759-2771.
[65] Fu Q, Chen X, Xiang Y. Compartmentalization of β-adrenergic signals in cardiomyocytes. Trends in Cardiovascular Medicine 2013;23:250-256.
[66] Verschure D, van Eck-Smit B, Somsen G, Verberne H. Cardiac sympathetic activity in hypertrophic cardiomyopathy and Tako-tsubo cardiomyopathy. Clinical and translational imaging 2015;3:379-385.
[67] D'Elia E, Ferrero P, Revera M, Iacovoni A, Gandolfi E, Senni M, et al. Clinical correlates of autonomic response during tilting test in hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine (Hagerstown, Md.) 2017;18:255-261.
[68] Prajapati C, Ojala M, Aalto-Setälä K. Divergent effects of adrenaline in human induced pluripotent stem cell-derived cardiomyocytes obtained from hypertrophic cardiomyopathy. Disease Models & Mechanisms 2018;11:
[69] Olmati F, Petramala L, Bisogni V, Concistré A, Saracino V, Oliviero G, et al. A rare case report of hypertrophic cardiomyopathy induced by catecholamine-producing tumor. Medicine 2018;97:e13369.
[70] Nash C, Wei W, Irannejad R, Smrcka A. Golgi localized β1-adrenergic receptors stimulate Golgi PI4P hydrolysis by PLCε to regulate cardiac hypertrophy. eLife 2019;8:
[71] Östman-Smith I. Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies. Reviews on Recent Clinical Trials 2014;9:82-85.